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SALM5 trans-synaptically interacts 
with LAR-RPTPs in a splicing-
dependent manner to regulate 
synapse development
Yeonsoo Choi1,*, Jungyong Nam1,*, Daniel J. Whitcomb2,*, Yoo Sung Song3,*, Doyoun Kim4, 
Sangmin Jeon5, Ji Won Um5,6, Seong-Gyu Lee1, Jooyeon Woo1, Seok-Kyu Kwon1, Yan Li4, 
Won Mah7, Ho Min Kim8, Jaewon Ko5, Kwangwook Cho2,9 & Eunjoon Kim1,4
Synaptogenic adhesion molecules play critical roles in synapse formation. SALM5/Lrfn5, a SALM/Lrfn 
family adhesion molecule implicated in autism spectrum disorders (ASDs) and schizophrenia, induces 
presynaptic differentiation in contacting axons, but its presynaptic ligand remains unknown. We 
found that SALM5 interacts with the Ig domains of LAR family receptor protein tyrosine phosphatases 
(LAR-RPTPs; LAR, PTPδ, and PTPσ). These interactions are strongly inhibited by the splice insert B 
in the Ig domain region of LAR-RPTPs, and mediate SALM5-dependent presynaptic differentiation 
in contacting axons. In addition, SALM5 regulates AMPA receptor-mediated synaptic transmission 
through mechanisms involving the interaction of postsynaptic SALM5 with presynaptic LAR-RPTPs. 
These results suggest that postsynaptic SALM5 promotes synapse development by trans-synaptically 
interacting with presynaptic LAR-RPTPs and is important for the regulation of excitatory synaptic 
strength.
Synaptic adhesion molecules with synaptogenic activity play important roles in several steps of synapse devel-
opment, including the initial contact between axons and dendrites, and formation and maturation of early 
synapses1–13.
The SALM (for synaptic adhesion-like molecules; also known as Lrfn for leucine-rich repeat and fibronectin 
type III domain containing) family of adhesion molecules contains five known members: SALM1/Lrfn2, SALM2/
Lrfn1, SALM3/Lrfn4, SALM4/Lrfn3, and SALM5/Lrfn513–16. SALMs share a similar domain structure, containing 
leucine-rich repeats (LRRs), an immunoglobulin (Ig) domain, and a fibronectin III (FNIII) domain, followed 
by a transmembrane domain and a C-terminal PDZ-binding motif. This motif, known to bind the postsynap-
tic scaffolding PDZ protein PSD-95, is present in SALMs 1–3, but not in SALMs 4–5, suggesting that SALMs 
have diverse functions. Further supporting the functional diversity of SALMs, SALM3 and SALM5 but not other 
SALMs induce presynaptic differentiation in contacting axons17. Notably, SALM4 and SALM5, but not other 
SALMs, display homophilic and trans-cellular adhesion18. This suggests that SALMs have both pre- and postsyn-
aptic functions, and that trans-synaptic, homophilic SALM5 adhesion may play important roles.
SALM5/Lrfn5 has been associated with severe progressive autism in which expression levels of SALM5 are 
markedly reduced (by ~90%) due to a balanced chromosomal translocation19–23. In addition, an inherited copy 
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number variation of SALM5 has been found in familial schizophrenia24,25. Therefore, SALM5-dependent pre-
synaptic induction may play critical roles in brain development and function. However, the presynaptic ligands 
that mediate SALM5-dependent presynaptic induction have remained elusive. In addition, it is unclear whether 
the main function of SALM5, which lacks PSD-95 binding, is to induce presynaptic differentiation, minimally 
contributing to postsynaptic functions.
LAR (for leukocyte common antigen-related) is a family of receptor protein tyrosine phosphatases (LAR-RPTPs) 
with three known members: LAR/PTPRF, PTPδ /PTPRD, and PTPσ /PTPRS. Early studies on Drosophila LAR 
implicated the protein in the regulation of axon guidance and synaptic development26,27. In mammals, LAR-RPTPs 
have been shown to regulate dendrite and excitatory synapse development and maintenance28,29. LAR-RPTPs inter-
act trans-synaptically with several postsynaptic adhesion molecules, including NGL-3, TrkC, IL1RAPL1, IL1RAcP, 
Slitrks, and SALM3 to promote synapse development30–39, and in cis manner with presynaptic glypicans and 
netrin-G140,41. Supporting their significant in vivo functions, mice lacking LAR, PTPδ , or PTPσ exhibit a variety of 
phenotypes, including reduced food intake and survival, endocrine defects, reduced neuronal growth and regener-
ation, altered synaptic plasticity, impaired learning and memory, and hyperactivity42–50. In humans, PTPδ has been 
implicated in ASDs, ADHD, bipolar disorder, and restless leg syndrome51–55, although the underlying mechanisms 
are largely unknown.
Here, we identified LAR-RPTPs as novel and splicing-dependent presynaptic ligands for SALM5, and demon-
strate that they mediate SALM5-dependent presynaptic differentiation. In addition, we found that SALM5 main-
tains AMPA receptor (AMPAR)-mediated excitatory synaptic transmission through mechanisms involving the 
interaction of SALM5 with LAR-RPTPs.
Results
SALM5 interacts with LAR-RPTPs. In order to identify a presynaptic ligand for SALM5, we performed 
cell aggregation assays in which one group of L cells expressing SALM5 was mixed with another group of L cells 
expressing candidate adhesion molecules (Supplementary Fig. 1). We found that SALM5-expressing cells coag-
gregated with cells expressing all three LAR-RPTPs (LAR, PTPδ , and PTPσ ). The reported transcellular, homo-
philic adhesion for SALM4 and SALM518 was not be observed in the form of green-cell aggregates in our assays, 
likely due to that we used floating L cells with a low adhesive background to make a high-stringency condition, 
whereas previous assays employed HeLa cells or hippocampal neurons attached to extracellular substratum. In 
addition, we could not observe self-aggregations of LAR-RPTPs, as also shown previously for PTPσ 56.
Other SALMs (SALM1, SALM2, SALM3, and SALM4) did not interact with LAR in cell aggregation assays 
(Fig. 1a,b). Soluble LAR, the ectodomain of LAR fused to the Fc domain of human Ig (LAR-Ecto-Fc), bound 
strongly to SALM5-expressing HEK293T cells, but much more weakly to SALM2 and not to other SALMs 
(Fig. 1c,d). In addition, LAR expressed in HEK293T cells induced clustering of SALM5 as well as Shank2, a post-
synaptic scaffold, in the neurites of cocultured hippocampal neurons (Fig. 1e,f; Supplementary Fig. 2).
The interaction between SALM5 and LAR was calcium-insensitive, as shown by the absence of an effect of 
the calcium chelator EGTA on the interaction (Fig. 1g,h). In order to determine the apparent binding affinity 
of the SALM5-LAR interaction, we incubated SALM5-expressing HEK293T cells with increasing amounts of 
LAR-Ecto-Fc. The Kd value of the SALM5-LAR interaction calculated by Scatchard analysis was 8.96 ± 0.92 nM 
(Fig. 1i). PTPδ and PTPσ also interacted with SALM5 in cell aggregation assays (Fig. 1j,k).
The LRR domain of SALM5 interacts with Ig domains of LAR. In order to determine the mini-
mal domains involved in the SALM5-LAR interaction, we generated deletion variants of SALM5 and LAR. A 
LAR variant containing the three Ig domains only (LAR-Ig) interacted with SALM5 in cell aggregation assays 
(Fig. 2a–c). In contrast, another region of LAR containing eight FNIII domains (LAR-FNIII) did not interact 
with SALM5, although it did interact with NGL-3 (Fig. 2a–c), a positive control known to interact with the 
first two FNIII domains of LAR, PTPδ , and PTPσ 30,32. In soluble protein binding assays, purified LAR-Ig (Ig1-3 
domains only) fused to Fc (LAR-Ig-Fc) bound to cells expressing SALM5 but not to those expressing SALM3 or 
NGL-3, whereas LAR-FN12-Fc (first two FNIII domains only) bound to NGL-3 but not to SALM3 or SALM5 
(Supplementary Fig. 3a–d). These results suggest that the Ig domains of LAR are sufficient to mediate SALM5 
binding, and indicate that two distinct domains of LAR mediate interactions with SALM5 (Ig domains) and 
NGL-3 (FNIII domains).
The deletion variants of SALM5 expressed in heterologous cells exhibited the predicted sizes and showed 
comparable surface expression, although some variants (Δ Ig and Δ FNIII) displayed lowered expression levels, 
likely due to protein degradation (Fig. 2d–f and Supplementary Fig. 3e,f). When tested for LAR binding in solu-
ble LAR-binding assays, a mutant SALM5 that lacked the FNIII domain but contained intact LRRs + Ig domains 
(SALM5-Δ FNIII) showed partially reduced LAR-Ecto-Fc binding comparable to that of full-length SALM5. 
Another SALM5 variant that lacked the LRR domain but contained intact Ig + FNIII domains (SALM5-Δ LRR) 
did not interact with LAR. A mutant SALM5 that lacked the Ig domain (SALM5-Δ Ig) did not reach the cell sur-
face. These results suggest that the LRR domain of SALM5 is required for LAR binding, and that the LRR + Ig 
domains of SALM5 are sufficient for LAR binding. In addition, the FNIII domain may also partially contribute 
to the interaction.
SALM5 directly interacts with LAR. To obtain biochemical evidence for the interaction, we tried coim-
munoprecipitation using soluble LAR fusion proteins (LAR-Ecto-Fc and LAR-Ig-FN14 [Ig + first four FNIII 
domains]) and soluble SALM5-Ecto, and found positive results (Fig. 3a–c).
Next, we tried a quantitative measurement of the direct interaction between LAR and SALM5 using soluble 
proteins and biolayer interferometry (BLI). SALM5-Ecto (containing the LRR + Ig domains but missing the 
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following FNIII domain) displayed weak bindings to LAR-Ig-FN12 and LAR-Ig with the Kd values in the micro-
molar range (38.5 and 16.6 μ M, respectively) but no binding to LAR-FN12 (Fig. 3d–g). These binding affinities 
are much lower than that for LAR-Ecto binding to SALM5 displayed on HEK293T cells (Kd of ~9 nM; Fig. 1i). 
It is possible that the SALM5 recombinant protein used in the current experiment may be in a suboptimal state 
for LAR binding, likely because we used a hybrid LRR version of SALM5 to increase protein expression levels 
Figure 1. SALM5, but not other SALMs, interacts with LAR-RPTPs. (a) SALM5, but not other SALMs, 
interacts with LAR in cell aggregation assays. A group of L cells doubly transfected with pDisplay constructs 
containing the ectodomains of SALMs (SALMs-Ecto-pDis) and EGFP was mixed with another group of L 
cells cotransfected with LAR-Ecto-pDis (meA−; meB−) and DsRed2 for cell aggregation. Scale bar, 100 μ m. (b) 
Quantification of the results in (A). Mean ± s.e.m. n = 10 fields of view, ** * p < 0.001, ANOVA-Tukey’s test. (c) 
SALM5 binds soluble LAR. HEK293T cells expressing SALMs-Ecto-pDis were incubated with LAR-Ecto-Fc 
(meA− and meB−). Scale bar, 50 μ m. (d) Quantification of the results in (c). n = 15 fields of view, * p < 0.05,  
* * * p < 0.001, ANOVA-Tukey’s test. (e) LAR-expressing HEK293T cells induce SALM5 clustering in contacting 
neurites of cocultured neurons. HEK293T cells expressing LAR (C-terminal ECFP tag) were cocultured with 
hippocampal neurons (DIV 14–17) transfected with SALM5 (N-terminal Myc tag; DIV 12–14). The large, 
discontinued SALM5 clusters are likely because they are different neurites and exogenously expressed proteins. 
Scale bar, 10 μ m. (f) Quantification of the results in (e). n = 10 cells for EGFP and 7 for LAR-ECFP,  
* * * p < 0.001, Student’s t-test. (g) Calcium-insensitive adhesion between SALM5 and LAR. Two groups of L cells 
expressing SALM5-Ecto-pDis and LAR-Ecto-pDis were mixed for cell aggregation in the presence of 10 mM 
EGTA, a calcium chelator. Scale bar, 100 μ m. (h) Quantification of the results in (g). n = 10, *** p < 0.001, ns, 
not significant, ANOVA-Tukey’s test. (i) Apparent affinity of the SALM5–LAR interaction measured by adding 
increasing amounts of LAR-Ecto-Fc to SALM5 (untagged)-expressing HEK293T cells. Inset, Scatchard plot 
analysis. (j) SALM5 interacts with PTPδ and PTPσ in cell aggregation assays. Note that we used the Ig domains 
of LAR-RPTPs because they mediate the SALM5 binding (see below for details). Scale bar, 100 μ m.  
(k) Quantification of the results in (j). n = 10, *** p < 0.001, ANOVA-Tukey’s test.
www.nature.com/scientificreports/
4Scientific RepoRts | 6:26676 | DOI: 10.1038/srep26676
(see Methods for further details). In addition, these in vitro experimental conditions may differ from the cellular 
context of the LAR binding assay (Fig. 1i).
Splice inserts in LAR-RPTPs differentially regulate SALM5 binding. The interaction of neurexins 
with neuroligins, LRRTM2, and Cbln1 + GluRδ 2 are regulated by short peptide inserts in neurexins generated 
by alternative splicing57–63. Similarly, alternative splicing regulates LAR-RPTP interactions with TrkC, Slitrks, 
IL1RAPL1, IL1RAcP, and SALM333,35,36,39. LAR-RPTPs contain short splice inserts in the Ig domains generated 
by mini exons (me) (Fig. 4a)64. Because the Ig domains of LAR mediated SALM5 binding, we tested whether the 
splice inserts in the Ig domains of LAR-RPTPs affected SALM5 binding.
We found that a splice insert of LAR from the first mini exon (meA; 6 amino acids) in the Ig domains had 
no additive effect on the interaction of LAR with SALM5 in cell aggregation assays using Ig domain-only LAR 
(Fig. 4a–c). The second mini exon (meB; 4 amino acids) in the Ig domains of LAR, however, significantly sup-
pressed the interaction. PTPδ also contains two splice inserts (meA and meB) in the Ig domains (Fig. 4a). Partly 
dissimilar to the results from LAR, meA and meB in PTPδ additively suppressed PTPδ binding to SALM5 with 
a stronger effect being exerted by meB (Fig. 4d,e). Similar results were obtained for PTPσ binding to SALM5 
(Fig. 4f,g).
Next, we used full-length LAR-RPTP proteins (not Ig domain only). We obtained similar results, as compared 
with those from Ig domain-only LAR-RPTPs, including that the meB insert strongly inhibits the interactions 
between SALM5 and LAR-RPTPs (Supplementary Fig. 4). However, a minor difference was that the meA insert in 
PTPσ , which inhibited the SALM5–PTPσ interaction (Ig domain-only PTPσ ), slightly promoted the interaction 
(full-length PTPσ ). This may be attributable to the different context of Ig domain-only and full-length constructs. 
Taken together, these results suggest that the meA and meB splice inserts in LAR-RPTPs differentially regulate 
SALM5 binding, and that the meB splice insert strongly inhibits the SALM5–LAR-RPTP interactions.
Soluble LAR inhibits SALM5-dependent presynaptic differentiation. If LAR is a presynaptic ligand 
involved in SALM5-induced presynaptic differentiation, soluble LAR (LAR-Ecto-Fc), which would compete with 
endogenous LAR for SALM5 binding, should be able to inhibit SALM5-dependent presynaptic induction. Indeed, 
LAR-Ecto-Fc (meB-negative) added to SALM5-expressing HEK293T cells cocultured with hippocampal neurons 
was able to reduce SALM5-induced presynaptic protein (synapsin I) clustering in contacting axons, whereas 
Figure 2. The LRR domain of SALM5 interacts with Ig domains of LAR. (a) Deletion variants of LAR 
used. TM, transmembrane domain; D1 and D2, tyrosine phosphatase domains. (b) The Ig domains of LAR 
mediate SALM5 binding. L cells expressing SALM5-Ecto-pDis, NGL-3 (untagged full-length, a positive 
control for LAR-FNIII), or HA-CD8 (a negative control), were mixed with other L cells expressing full-length 
or deletion variants of LAR-pDis for cell aggregation. Scale bar, 100 μ m. (c) Quantification of the results in 
(b). Mean ± s.e.m. n = 10 fields of view, *** p < 0.001, ANOVA-Tukey’s test. (d) Deletion variants of SALM5 
generated from full-length Myc-SALM5. (e) SALM5-Δ FNIII containing LRR + Ig domains binds LAR, 
whereas SALM5-Δ LRR, which lacks the LRR domain, fails to bind LAR. HEK293T cells expressing SALM5 
deletion variants were incubated with LAR-Ecto-Fc, followed staining for surface Myc (SALM5) and human-Ig 
(LAR-Ecto-Fc). Note that SALM5-Δ Ig fails to reach the cell surface. (f) Quantification of the results in (e), by 
normalizing bound LAR to surface Myc signals. n = 10 fields of view, *** p < 0.001, ANOVA.
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Fc alone (a negative control) had no effect (Fig. 5a,b). In control experiments, LAR-Ecto-Fc (meB-negative) 
had no effect on SALM3-induced synapsin I clustering, similar to Fc alone (Fig. 5c,d), whereas another form of 
LAR-Ig-Fc (meB-positive) could inhibit SALM3-induced synapsin I clustering (Supplementary Fig. 5). These 
results suggest that LAR is important for presynaptic differentiation induced by SALM5.
LAR-RPTPs mediate SALM5-dependent presynaptic differentiation. As an independent way to 
test the role of LAR in SALM5-dependent presynaptic differentiation, we attempted to generate a mutant SALM5 
that lacked LAR binding, which would be unable to induce presynaptic differentiation. In alanine-scanning 
mutagenesis of the residues that are uniquely present in the ectodomain of SALM5 but not in other SALMs, we 
found that a double-alanine mutation of Ser329 and Ser360 (S329/360A) in the Ig domains of SALM5 signifi-
cantly decreased SALM5 binding to LAR-Ecto-Fc (Fig. 5e,f). A similar result was obtained in cell aggregation 
assays (Fig. 5g,h). SALM5-S329/360A also showed weakened interactions with PTPδ and PTPσ in cell aggrega-
tion assays (Supplementary Fig. 6a–d).
Importantly, SALM5-S329/360A, but not wild-type (WT) SALM5, failed to induce synapsin I clustering in 
contacting axons in coculture assays (Fig. 5i,j). These results suggest that SALM5-dependent presynaptic differ-
entiation is mediated by LAR-RPTPs. A control experiment in which the synapsin I clustering induced by SALM5 
was normalized by tau, a marker of axonal fibers, to exclude the contribution of axon aggregation gave a similar 
result (data not shown).
We reasoned that SALM5-S329/360A, which lacks LAR binding but retains other domains intact, may exert a 
dominant-negative effect when overexpressed in neurons. Indeed, SALM5-S329/360A overexpressed in cultured 
hippocampal neurons reduced the density of synapsin I clusters along the dendrites (Supplementary Fig. 6e–g).
Lastly, when SALM5-expressing HEK293T cells were cocultured with hippocampal neurons infected with 
lentivirus carrying one of the three LAR-RPTP knockdown constructs38, PTPσ knockdown had apparently the 
strongest effect on SALM5-dependent synapsin I clustering whereas LAR or PTPδ knockdown had relatively 
small effects (Fig. 5k,l). In control experiments, the expression levels of LAR, PTPδ , and PTPσ mRNAs were 
Figure 3. SALM5 directly interacts with LAR. (a–c) Coprecipitation between recombinant ectodomains 
of SALM5 and LAR. LAR ectodomain proteins (LAR-Ecto-Fc or LAR-IgFN14-Fc [Ig1-3 + FN1-4]) 
and HA-SALM5-Ecto secreted from transfected HEK293T cells into the supernatant were subjected to 
immunoprecipitation (IP) and immunoblot analysis. (d–g) Direct interaction between purified, soluble LAR 
and SALM5 fusion proteins, measured by the biolayer interferometry. Hybrid SALM5-Ecto proteins binds LAR-
Ig-FN12 and LAR-Ig but not to LAR-FN12 fusion proteins (d–f), which is summarized in a schematic diagram 
(g). A hybrid SALM5 protein was used to increase protein expression levels (see Materials and methods for 
details). Note that the LAR constructs longer than the Ig domains only used here (LAR-FN12) and in the 
coimmunoprecipitation experiments (LAR-Ig-FN14) would not interfere with demonstrating the direction 
interaction of LAR with SALM5, as evident in Fig. 2a–c.
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similarly reduced by the individual knockdown constructs, down to ~20% of normal levels (Supplementary 
Fig. 7a). In addition, an shRNA-resistant PTPσ rescue construct could normalize SALM5-dependent synapsin 
I clustering to ~75% of original levels (Supplementary Fig. 7b,c), indicating that the effect of PTPσ knockdown 
is largely specific. These results collectively suggest that presynaptic LAR-RPTPs are important mediators of 
SALM5-induced presynaptic differentiation in the hippocampus.
SALM5 regulates AMPAR-mediated synaptic transmission through LAR interaction. To explore 
the role of SALM5 in the regulation of synaptic function, we reduced the expression of SALM5 using shRNA 
transfection in organotypic hippocampal slice cultures (at DIV 3–4), followed by the measurement of excitatory 
synaptic transmission at Schaffer collateral (SC)-CA1 pyramidal synapses (at DIV 6–8).
SALM5 knockdown in CA1 pyramidal neurons caused significant decrease in AMPAR-mediated excitatory 
postsynaptic currents (EPSCAMPA) relative to neighboring untransfected cells, although there was a strong ten-
dency for a decrease of NMDA receptor (NMDAR)-mediated EPSCs (EPSCNMDA) (p = 0.052) (Fig. 6a).
Coexpression of shRNA-resistant rescue SALM5 together with the SALM5 knockdown construct rescued 
EPSCAMPA (Fig. 6b), indicating that the knockdown construct is specific. However, the rescue construct failed to 
rescue the reduced EPSCNMDA, indicative of an off-target effect for NMDAR function. When a mutant SALM5 
(S329/S360A) that lacks LAR binding was used in the rescue experiment, it failed to rescue EPSCAMPA (Fig. 6c).
To gain further insights into the underlying mechanism, we knocked down SALM5 in hippocampal slice 
culture and found that SALM5 knockdown in CA1 pyramidal neurons substantially decreases the frequency but 
not amplitude of both miniature excitation postsynaptic currents (mEPSCs) and miniature inhibitory postsyn-
aptic currents (mIPSCs) (Fig. 6d,e). These results collectively suggest that SALM5 regulates AMPAR-mediated 
synaptic transmission through mechanisms involving the interaction of postsynaptic SALM5 with presynaptic 
LAR-RPTPs, and that SALM5 regulates inhibitory synaptic transmission in addition to excitatory synaptic trans-
mission, similar to the results from dissociated neurons17.
Discussion
In the present study, we identified LAR-RPTPs as novel ligands of SALM5 that mediates SALM5-dependent pre-
synaptic differentiation in a splicing-dependent manner.
Our data indicate that SALM5 interacts with all three known LAR-RPTPs—LAR, PTPδ , and PTPσ (Fig. 1). 
mRNAs for LAR, PTPδ , and PTPσ mRNAs display overlapping as well as differential distribution patterns in var-
ious brain regions32. In addition, SALM5 mRNAs are detected in various brain regions14,16, suggesting that their 
interactions may be widespread in the brain.
Pre- or postsynaptic localization of SALM5 and LAR at the ultrastructural level has not been determined 
due to the lack of suitable antibodies17,30. Previous and current results, however, suggest that postsynaptic 
Figure 4. Splice inserts in the Ig domains of LAR, PTPδ, and PTPσ differentially regulate SALM5 binding. 
(a) Splice inserts (meA and meB) in the Ig domains of LAR-RPTPs. (b) The meB, but not meA, insert in LAR 
suppresses LAR binding to SALM5 in cell aggregation assays using the ectodomain of SALM5 and Ig domains 
of LAR (both in pDis). Scale bar, 100 μ m. (c) Quantification of the results in (b). Mean ± s.e.m. n = 12 fields of 
view, *** p < 0.001, ANOVA-Tukey’s test. (d) Splice inserts (meA and meB) in PTPδ additively inhibit SALM5 
binding. Scale bar, 100 μ m. (e) Quantification of the results in (d). n = 10, * p < 0.05, ** p < 0.01, *** p < 0.001, 
ANOVA-Tukey’s test. (f) Splice inserts (meA and meB) in PTPσ additively inhibit SALM5 binding. Scale bar, 
100 μ m. (g) Quantification of the results in (f). n = 10, *** p < 0.001, ANOVA-Tukey’s test.
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SALM5 likely interacts with presynaptic LAR-RPTPs; 1) SALM5 expressed in heterologous cells or neurons 
induces presynaptic protein clustering, whereas SALM5 does not induce postsynaptic protein clustering17, and 
2) presynaptic LAR-RPTPs interact with various postsynaptic adhesion molecules, including NGL-3, TrkC, 
IL1RAPL1, IL1RAcP, and Slitrks30,32–38. However, it is possible that SALM5 may be presynaptically localized and 
trans-synaptically interacts with postsynaptic SALM5 to regulate synapses, as supported by the reported transcel-
lular, homophilic interaction of SALM5 in heterologous cells and cultured neurons18.
The Ig domains of LAR-RPTPs mediate SALM5 binding. This is similar to the reported Ig domain-dependent 
interactions of LAR-RPTPs with TrkC, IL1RAPL1, IL1RAcP, Slitrks, and SALM333–36,39, but differs from the 
FN12-dependent interaction of LAR-RPTPs with NGL-330,32. These results suggest that distinct domains of 
LAR-RPTPs mediate trans-synaptic interactions.
The meB splice insert strongly inhibits the interactions between LAR-RPTPs and SALM5 (Fig. 4 and 
Supplementary Fig. 4). This is similar to the reported meB-dependent inhibition of PTPσ binding to TrkC33, but 
Figure 5. LAR-RPTPs mediate SALM5-dependent presynaptic differentiation. (a) Soluble LAR inhibits 
SALM5-dependent synapsin I clustering. SALM5-expressing HEK293T cells were cocultured with hippocampal 
neurons in the presence of LAR-Ecto-A−B—Fc, or Fc alone, followed by immunostaining for synapsin I and 
SALM5 (HA). Scale bar, 15 μ m. (b) Quantification of the results in (a). Mean ± s.e.m. n = 39 fields of view for Fc 
alone and 33 for LAR-Ecto-Fc, *** p < 0.001, Student’s t-test. (c) Soluble LAR does not inhibit SALM3-induced 
synapsin I clustering. Scale bar, 15 μ m. (d) Quantification of the results in (c). n = 26 for Fc alone and 17 for LAR-
Ecto-Fc, ns, not significant, Student’s t-test. (e) A SALM5 mutant (S329/360A) shows reduced LAR binding. 
HEK293T cells expressing SALM5-Ecto-pDis, SALM5-Ecto-S329/360A-pDis, or SALM3-Ecto-pDis, were 
incubated with LAR-Ecto-Fc. Scale bar, 10 μ m. (f) Quantification of the results in (e). n = 10, * p < 0.05,  
*** p < 0.001, ANOVA-Tukey’s test. (g) SALM5-S329/360A shows reduced binding to LAR. Scale bar, 100 μ m.  
(h) Quantification of the results in (g). n = 10 fields of view, * p < 0.05, *** p < 0.001, ANOVA-Tukey’s test.  
(i) SALM5-S329/360A fails to induce synapsin I clustering in contacting axons. HEK293T cells expressing 
SALM5-Ecto-pDis, SALM5-Ecto-S329/360A-pDis, or EGFP alone, were cocultured with hippocampal neurons, 
followed by staining for synapsin I, SALM5 (HA), and EGFP. Scale bar, 10 μ m. (j) Quantification of the results in 
(i). n = 13 cells for EGFP, 15 for SALM5-Ecto-pDis (WT and S329/360A), *** p < 0.001, ANOVA-Tukey’s test.  
(k) SALM5-dependent presynaptic synapsin I clustering is significantly reduced by knockdown of PTPσ but to 
a much lesser extent by LAR or PTPδ . Hippocampal neurons infected at DIV 3–4 with LAR-RPTP knockdown 
lentiviruses (sh-control/LAR/PTPδ /PTPσ ) were cocultured for 3 days (DIV 10–13) with HEK293T cells 
expressing EGFP alone, or EGFP + SALM5-pDis, followed by staining for EGFP and synapsin I. Scale bar, 10 μ m. 
(l) Quantification of the results in (k); synapsin I signals were normalized to EGFP fluorescence. n = 33 cells for 
EGFP/sh-Control, 22 for SALM5 + sh-Control/sh-PTPσ shRNA, and 19 for SALM5 + sh-LAR/sh-PTPδ ,  
** * p < 0.001, ANOVA-Tukey’s test.
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contrasts with the meB-dependent interactions of LAR-RPTP with SALM3 and Slitrks39,56. It should be pointed 
out that the negative interaction between LAR and SALM3 in the present study (Fig. 1a–d) appears to be caused 
by the absence of the meB insert in our LAR constructs, as supported by the inhibition of SALM3-dependent 
presynaptic differentiation by LAR-Ecto-Fc containing the meB splice insert (Supplementary Fig. 5).
The meA splice had mixed influences on LAR-RPTP–SALM5 interactions, not affecting the LAR inter-
action, suppressing the PTPδ interaction, and both enhancing and suppressing the PTPσ interaction in a 
context-dependent manner. The positive regulation is reminiscent of meA-dependent interaction of PTPδ with 
IL1RAPL1 or IL1RAcP35,36, and the negative regulation is similar to the meB-dependent inhibition of PTPσ inter-
action with TrkC33. A similar bidirectional regulation has also been reported for neurexins; SS#4 (a 30-amino-acid 
insert at splice site #4) in neurexins enhances its interactions with Cbln1 and GluRδ 262, whereas it inhibits neu-
rexin binding to LRRTM260,61 and neuroligins58,59,63.
Our data implicate SALM5 in the regulation of AMPAR-mediated synaptic transmission. The AMPA-EPSC 
data suggest that SALM5 regulates AMPAR transmission through mechanisms involving the interaction of 
SALM5 with LAR-RPTPs. In addition, the mEPSC data, together with the known synaptogenic activities of 
SALM517 and LAR-RPTPs2,4, suggests that SALM5 regulates AMPAR transmission through the modulation of the 
number but not strength of individual excitatory synapses. These modulations likely involve postsynaptic SALM5 
because the slice knockdown of SALM5 occurs in CA1 pyramidal postsynaptic neurons. In addition, it is likely to 
involve presynaptic LAR-RPTPs because the frequency but not amplitude of mEPSCs was decreased. However, 
postsynaptic LAR-RPTPs have been suggested to play important roles in the development and maintenance of 
Figure 6. SALM5 regulates AMPAR EPSCs through mechanisms involving LAR interaction. (a) SALM5 
knockdown reduces EPSCAMPA in transfected neurons relative to untransfected neurons, whereas it has no 
effect on EPSCNMDA, although there was a strong tendency for a decrease (p = 0.052). n = 16. * p < 0.05 for 
EPSCAMPA, Student’s t-test. (b) Specificity of the SALM5 knockdown construct determined by the coexpression 
of the rescue construct. Neurons in slice cultures were transfected with sh-SALM5 + shRNA-resistant SALM5 
(DIV 3–4), and EPSCAMPA or EPSCNMDA were measured at SC-CA1 synapses at DIV 6–8. n = 16. * p < 0.05 
for EPSCAMPA (SALM5 rescue), Student’s t-test. Note that the SALM5 rescue construct does not rescue the 
reduced EPSCNMDA, indicative of an off-target effect. (c) A mutant SALM5 (SALM5-S329/S360A) lacking LAR 
interaction fails to rescue SALM5-knockdown dependent suppression of EPSCAMPA. The experiments were 
performed as described in (b), expect that a mutant form of SALM5 was used. n = 16. * p < 0.05 for EPSCAMPA 
(SALM5-S329/S360A rescue), Student’s t-test. (d,e) SALM5 knockdown suppresses the frequency but not 
amplitude of mEPSCs and mIPSCs in the CA1 pyramidal neurons of the hippocampus. Neurons in slice 
cultures were transfected with sh-SALM5 (DIV 3–4), and mEPSCs and mIPSCs were measured in CA1 neurons 
at DIV 6–8. n = 11 cells for mEPSC and 12 cells for mIPSC, * p < 0.05, Student’s t-test.
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excitatory synapses, as supported by, for example, the decreases in both frequency and amplitude of mEPSCs by 
the inhibition of postsynaptic LAR-RPTPs28. Therefore, whether postsynaptic or even presynaptic SALM5 inter-
acts with postsynaptic LAR-RPTPs to regulate AMPARs remains to be determined.
Lastly, SALM5/Lrfn5 has been implicated in ASDs and schizophrenia19–22,24,25. In addition, PTPδ is implicated 
in ASDs, ADHD, bipolar disorder, and restless leg syndrome51–55,65. Therefore, our findings might eventually help 
us understand the mechanisms underlying SALM5- and LAR-RPTP-related brain dysfunctions.
In conclusion, we have identified LAR-RPTPs as novel and splicing-dependent ligands that mediate 
SALM5-dependent presynaptic differentiation. In addition, SALM5 regulates AMPAR-mediated synaptic trans-
mission through mechanisms involving the interaction with LAR-RPTPs. These results suggest that SALM5 con-
tributes to synapse development and maintenance.
Materials and Methods
DNA constructs and antibodies. For Myc tagging of SALMs, the epitope was inserted between aa 16 and 
17 of mouse SALM3 and aa 19 and 20 of mouse SALM5, respectively, in pGW1 (British Biotechnology). The Myc 
epitope of SALM5-Ecto-pDis was replaced with stop codon to generate N-terminally HA-tagged soluble SALM5-
Ecto. For LAR-IgFN14-Fc, Ig1-3 + FN1-4 of LAR (aa 1-699) were subcloned into pFc-N1 (modified pEGFP-N1 
in which EGFP was replaced with human Fc). The following LAR-RPTP deletion variants were subcloned into 
pDisplay (Invitrogen): human LAR-Ig (aa 17–308), human LAR-Ig-A−B+ and LAR-Ig- A+B+ (aa 30–318), human 
PTPδ -Ig (aa 21–309), human PTPσ -Ig (aa 30–318). For LAR-Ig-Fc, the signal peptide of Ig-kappa and the Ig 
domains of LAR were subcloned into pFc-N1. Myc-SALM5 deletion variants were subcloned region into GW1: 
Myc-SALM5-Δ LRR (Δ aa 20–285), Myc-SALM5-Δ Ig (Δ aa 299–364), Myc-SALM5-Δ FNIII (Δ aa 408–495). 
Splice variants of the Ig domains of LAR-RPTPs were subcloned into pDisplay. Full-length mouse PTPσ , PTPδ , 
and LAR have been previously described: PTPσ -A−B−-CFP, PTPσ -A+B−-CFP, PTPσ -A−B+-CFP, PTPσ -A+B+-
CFP33, PTPδ -A−B−, PTPδ -A+B−, PTPδ -A−B+, PTPδ -A+B+, LAR- A−B−, LAR- A+B−, LAR- A−B+, and LAR- 
A+B+ in pcDNA3 vector35. Point mutants of SALM5-Ecto-pDis, untagged SALM5 in pGW1, and SALM5 in 
pIRES were generated using the Quickchange kit (Stratagene). The following constructs have been described pre-
viously: LAR-Ecto-pDis, LAR-FNIII-pDis32, SALMs 1-5-Ecto-pDis, untagged SALM5, sh-SALM517, HA-CD814, 
LAR-Ig-A−B−-pDis, LAR-Ig-A+B−-pDis56, NGL-3-EGFP, LAR-ECFP, LAR-Ecto-Fc30, shRNA lentiviral expres-
sion constructs for LAR-RPTPs38, and shRNA-resistant SALM5 (wild-type; pIRES-SALM5)17. The following anti-
bodies have been described previously: EGFP (1431)30, SALM5 (1907)17, and Shank266. The following antibodies 
were purchased: Myc, HA (Santa Cruz), synapsin I (Millipore), and α-tubulin (Sigma).
Cell aggregation assay. Cell aggregation assays were performed as described32. Briefly, two L-cell groups 
were transfected with EGFP + SALMs-Ecto-pDis, or RFP (DsRed) + LAR-Ecto-pDis. After 24 hours, L cells were 
trypsinized and resuspended in DMEM, followed by L cell mixing and rotation at room temperature for 2 hours 
for aggregation. Areas of cell aggregates in pixels were calculated using MetaMorph, and those that fall below of 
the size of an average single cell were removed and used to calculate an average aggregate size in arbitrary units 
(AU).
Soluble LAR-binding assay. Purified soluble LAR-Ecto-A−B−-Fc (10 μ g/ml) was added to 
SALM-expressing live HEK293T cells and incubated for 2 hours. Without permeabilization, cells were fixed 
with 4% paraformaldehyde/4% sucrose and incubated with antibodies. For quantitative LAR-binding assays, 
SALM5-expressing HEK293T cells were transferred to 96-well plates and grown for 24 hours. After fixation in 4% 
paraformaldehyde/4% sucrose, cells were incubated with increasing concentrations of LAR-Ecto-Fc for 1 hour, 
followed by incubation with HRP-conjugated anti-human-Fc antibodies (Sigma) and color reaction with 3,3′ ,5,5′ 
-Tetramethylbenzidine (Sigma). Integrated intensities of bound proteins in a field of view were normalized by 
those of the proteins expressed in the cells.
Recombinant protein expression and purification. The Ig1-3-FNIII12 domain (aa 27A–513A), Ig1-
3-A+B+ (aa 30D-318L), and FN12 (aa 312Q–510G) of human LAR were cloned into pAcGP67 (BD Bioscience), 
modified for C-terminal protein-A tagging. Since human SALM5 was hardly expressed in High Five insect cells 
(Invitrogen), hybrid LRR techniques were used to generate a chimeric hySALM5 proteins67. Briefly, the N ter-
minus of VLRB61 (1M–82L) was combined with the LRR and Ig domains of human SALM5 (aa 59A–374I) by 
overlap PCR, and the resulting chimeric gene for hySALM5 was cloned into pVL1393 (Invitrogen), modified 
for C-terminal Fc tagging. All constructs described above contain a thrombin cleavage site (LVPRGS) between 
target proteins and tags. The High Five insect cells were transfected with corresponding P4 baculovirus for 3 days 
and harvested. The supernatants containing secreted proteins were loaded onto IgG sepharose column to purify 
protein A-fused proteins, or onto protein A sepharose column to purify Fc-tagged protein. The protein A or Fc 
tags were thrombin cleaved (0.5% v/v) for 16 hours at 4 °C, followed by gel-filtration purification using Superdex 
200 (GE Healthcate Life Science).
Biolayer interferometry (BLI). For in vitro binding assays using the BLItz system (ForteBio), purified 
proteins were prepared in low salt buffer (20 mM HEPES, 50 mM NaCl, pH 7.0). Prior to the assay, protein A 
biosensors were hydrated in MilliQ for 10 min, followed by equilibration in a low salt buffer for 60 s. 10 μ M of 
LAR-Ig-A−B− (Ig1-3)-Fc, LAR-FN12 (FNIII1-2)-Fc, or hySALM5-Ecto (LRR + Ig-A−B−)-Fc was immobilized 
to the equilibrated sensors for 120 s. After dissociation, the primed biosensors were used to analyse the inter-
action between immobilized proteins and analytes. Three different analyte concentrations were used with the 
same primed biosensors. For LAR-Ig-FN12, which could not be purified, hySALM5-Ecto-Fc was pre-bounded 
to the equilibrated sensors. At the end of each association-dissociation steps, a high salt buffer (20 mM HEPES, 
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1M NaCl, pH 7.0) was used to wash off analytes from the primed biosensors. Affinity constants were determined 
using the global fitting function in the advanced kinetic program of BLItz.
Mixed-culture assay. Mixed-culture assays were performed as described68. Briefly, primary hippocampal 
neuron cultures at DIV 9/10 prepared from E18–19 rat hippocampi were cocultured with HEK293T cells express-
ing SALMs/CD8, followed by immunostaining at DIV 12/13. Hippocampal neurons were transfected for three 
days prior to coculture. For competitive inhibition, Fc alone, LAR-Ecto-A−B−-Fc, or LAR-Ig-A+B+-Fc (10 μ g/ml), 
were added to neuron-HEK293T cocultures for 3 days (DIV 9/10–12/13). Mixed-culture assays under lentiviral 
knockdown conditions were performed with as described60. Briefly, cultured hippocampal neurons were infected 
at DIV3–4 with the lentiviruses expressing shRNAs for LAR, PTPδ , or PTPσ 38, and incubated until HEK293T 
cells transfected with EGFP, or pDisplay-LAR, for 48 hours were added at DIV 10. At DIV13, the cells were 
double-immunostained for EGFP and synapsin. Levels of knockdowns were determined in parallel by quantita-
tive RT-PCR. For image quantification, fluorescence intensity of synapsin I puncta was normalized to cell area 
using MetaMorph (Molecular Device).
Lentivirus production. To generate the recombinant lentiviruses, human embryonic kidney 293T cells were 
transfected with three plasmids—L-309 vectors (L-309 LAR KD, L-309 PTPδ KD, L-309 PTPσ , or L-309 alone), or 
L-313 PTPσ -A−B−, PAX2, and pMD2G—using FuGENE-6 (Roche), as previously described69.
Transfection of neurons and immunocytochemistry. Cultured hippocampal neurons were transfected 
using mammalian transfection kit (Clontech), or lipofectamine LTX and PlusTM Reagent (Invitrogen), fixed with 
4% paraformaldehyde/4% sucrose, and permeabilized with 0.2% Triton x-100 in phosphate buffered saline, fol-
lowed by incubation with primary antibodies and Cy3-, Cy5-, or FITC-conjugated secondary antibodies (Jackson 
ImmunoResearch).
Image acquisition and quantification. All z-stacked images were randomly acquired by confocal micros-
copy (LSM510 and LSM780, Zeiss). For quantification of cell aggregation and Fc-binding assays, each field of view 
was counted as n of 1. For coculture assays and electrophysiology experiments, each cell or neuron was counted as 
n of 1. The results presented in all figures are from one set of experiments, although essentially the same conclu-
sions were obtained from additional independent experiments (mostly once or twice more) with the exception of 
electrophysiology (Fig. 6) for which data from two to three independent experiments were pooled.
Slice electrophysiology. Hippocampal slices (350 μ m; 6–8-day-old Wistar rat; McIlwain tissue chopper) 
were cultured on semipermeable membrane inserts (Millipore) in a six-well plate containing culture medium 
(78.8% MEM, 20% heat-inactivated horse serum, 25 mm HEPES, 10 mM D-glucose, 26 mM NaHCO3, 2 mM 
CaCl2, 2 mM MgSO4, 0.0048% 25% Ascorbic Acid, 0.1% 1 mg/ml Insulin, pH 7.3, 320–330 mOsm). Slices were 
cultured for DIV 6–8 with changes of media without antibiotics every 2 days. Neurons were transfected using 
a biolistic gene gun (Helios Gene-gun system) at DIV3–4 (100 μ g DNA; 90% test constructs; 10% pEGFP-C1). 
Electrophysiological recordings were performed at 3–4 days after transfection.
For whole-cell patch recordings, cultures were superfused with a warmed (28°–29°C) recording solution 
which comprised: (mM) NaCl, 119; KCl, 2.5; NaHCO3, 26; NaH2PO4, 1; MgCl2, 4; D-glucose, 11; CaCl2, 4 with 
added 10 μ M chloro adenosine and 20 μ M picrotoxin. A stimulating electrode was placed in SC-CA1 input, and 
neighbouring transfected and untransfected neurons were whole-cell patch clamped. Every 15 s, stimuli were 
delivered to the electrode (0.033 Hz). EPSCAMPA was estimated as the peak EPSC amplitude at a holding potential 
of − 70 mV, and EPSCNMDA was estimated at a holding potential of + 40 mV measured 80− 90 msec after the peak 
EPSCAMPA. Only cells that had an initial Rs (series resistance) < 20 MΩ with < 20% changes during recording were 
included in data analysis. mEPSCs were recorded in the presence of 20 μ M picrotoxin, 1 μ M bicuculline (Tocris) 
and 0.5 μ M tetrodotoxin (Abcam). mIPSCs were recorded in the presence of 10 μ M CNQX (HelloBio), 50 μ M 
AP5 (HelloBio), and 0.5 μ M tetrodotoxin. mEPSCs (holding potential, − 70 mV) and mIPSCs (holding potential, 
0 mV) were analyzed by Mini Analysis Software (Synaptosoft), with minimum event detection threshold values 
of 15 pA and 20 pA for mEPSCs and mIPSCs, respectively.
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